与尼沃卢马布和小分子抗血管原药相关的不良反应:药监测分析
Haiyang Li1, Zhaohui Ruan2, Yanan Jia3
1Department of Otorhinolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
British journal of clinical pharmacology
|September 17, 2024
概括
与检查点抑制剂和TKI结合免疫疗法增加了敏感皮肤和细胞癌的风险. 这项研究确定了关键的不良药物反应,以帮助瘤学家在患者管理中.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 免疫治疗是一种免疫疗法.
背景情况:
- 免疫检查点抑制剂 (ICI) 与小分子抗血管新生受体氨酸激酶抑制剂 (TKI) 结合,对癌症治疗有望.
- 组合疗法可能导致特定的药物不良反应 (ADR),但该领域的研究是有限的.
- 评估这种组合策略的安全概况对于临床应用至关重要.
研究的目的:
- 评估安全性并确定与ICI和TKI组合相关的药物不良反应 (ADR).
- 分析ADR风险信号,并比较不同瘤类型中致命ADR的发生率.
主要方法:
- 使用FDA不良事件报告系统数据库 (2012年第一季度 - 2023年第三季度) 进行的大规模回顾性研究.
- 对涉及ICI和TKI的组合治疗的ADR报告的分析.
- 使用报告几率比率 (ROR) 和RO/E比率对ADR风险信号的评估.
主要成果:
- 联合治疗显著增加了敏感皮肤 (ROR: 231.43),转移性细胞癌 (ROR: 220.71) 和细胞癌 (ROR: 188.22) 的风险.
- 根据特定的TKI组合和瘤类型观察到ADR的差异.
- 分析了容易发生致命ADRs的患者的特征.
结论:
- 这些发现增强了对与ICI-TKI联合治疗相关的ADRs的理解.
- 结果可以帮助瘤学家为接受这种治疗的患者制定查方案.
更多相关视频
04:48Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
Published on: January 7, 2015
7.4K
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
1.2K
相关概念视频
Pharmacovigilance
788
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
788
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
154
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
154
Combined Effects of Drugs: Antagonism
8.4K
The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
8.4K
